We requested details regarding the geographical and temporal distribution of the HUS/TTP reports. Consistent with our observations in the United Kingdom, very few cases were reported globally in the first 9 years of safety monitoring. However, there has been a recent increase in reports from countries that share the same formulation as that used in the United Kingdom. 3 Substantial caution is required in the interpretation of spontaneous reports of adverse drug reactions, since such reports are voluntary, are potentially subject to underreporting, and may be influenced by many factors, including the severity of the drug reaction, the diagnostic classification, and the degree of publicity. However, we did not detect such patterns or trends in the safe ty data from a similar recombinant interferon beta product, suggesting that further investigation of the association with changes in manufacturing may be worthwhile. We have raised these concerns with the manufacturer and regulatory authorities.
The patients in our analysis share important clinical features (for details, see the Supplementary Appendix). First, all the patients presented after years of well-tolerated treatment with inter-feron beta, making an association difficult to recognize. Second, fulminant presentation was associated with severe hypertension. Third, despite the emergency presentation, retrospective review identified chronic changes in all renal-biopsy specimens and a prodrome in three of the four patients with features that included newly diagnosed hypertension, hematologic abnormalities, and renal impairment in the months before diagnosis. We subsequently identified a similar prodrome in a recent fatal case in the United Kingdom. Thrombotic microangiopathy is therefore a serious and potentially fatal complication that has emerged late in the lifetime of recombinant inter-feron beta therapy. Early manifestations of this complication may be recognizable with increased vigilance, with the potential to mitigate severity.
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